RxDoctor Payments Data

John Rutledge, MD

Psychiatry · Saint Louis, MONPI 1124129549

Payments from drug & device makers

$736in general payments, 2019–2025

Across 33 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$177
  • AbbVie$146
  • Harmony Biosciences LLC$135
  • Corium, LLC$126
  • Ironshore Pharmaceuticals Inc.$84
  • Lundbeck LLC$30
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$70696%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 65th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$77,352
Medicare patients
30
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate46$25,758
VraylarCariprazine Hcl14$22,922
Aripiprazole69$7,094
BelsomraSuvorexant15$6,347
TrintellixVortioxetine Hydrobromide11$4,849
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine123$4,054
Fluvoxamine Maleate101$3,923
Lisdexamfetamine Dimesylate13$2,887
Quetiapine Fumarate45$1,901
Alprazolam118$1,332
Duloxetine Hcl81$975
Clonazepam91$815
Trazodone Hcl116$800
Atomoxetine Hcl20$722
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$177$30,60757 claims
AbbVieVraylar$146$22,92214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →